Combination therapy for COPD

a technology of copd and aerosol solution, which is applied in the direction of aerosol delivery, packaging goods type, drug composition, etc., can solve the problems of relatively unstable aerosol solution of formoterol fumarate and short shelf li

Inactive Publication Date: 2011-06-23
CHIESI FARM SPA
View PDF8 Cites 27 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

dissolved in HFA propellant and a co-solvent, wherein the formulation also comprises an inorganic acid a

Problems solved by technology

It has long been known that aerosol solutions of formoterol fumarate are relativ

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

A. Stability of Single, Double, and Triple Combination Aerosol Solution Formulations

A study was performed to investigate the stability of a triple combination of formoterol fumarate (FF), glycopyrronium bromide (GLY), and beclometasone dipropionate (BDP) in an aerosol solution formulation, in canister packaging under varied storage conditions:

In addition to the triple combination, the double combinations (FF+BDP; FF+GLY) and the single agent (GLY) were included in the study to evaluate whether any potential interactions between the active ingredients could affect drug stability. GLY as single agent was formulated with and without 1M HCl to evaluate the stabilizing effect of the acid. The batch compositions are summarized in Table 1:

TABLE 1Theoretical unit formulation (μg / actuation for a 63 μl valve)BatchAnhydrous1MHFAdescriptionBDPFFGLYethanolHCl134aTotalFF + GLY.6258856146489973800FF + GLY +1006258856146479973800BDPGLY——258856—6491973800GLY + acid——258856146490573800FF + BDP1006—88...

example 2

Stability of the Triple Combination Aerosol Solution Formulations

A study was performed to investigate the stability of a triple combination of formoterol fumarate (FF), glycopyrronium bromide (GLY), and beclometasone dipropionate (BDP) in an aerosol solution formulation with different levels of 1M HCl to evaluate the stabilizing effect of the acid, in conventional aluminum canisters, provided with standard EPDM valves crimped under varied conditions (i.e. with or without oxygen removal by vacuum crimping). The batch compositions are summarised in Table 5:

TABLE 5Theoretical unit formulation (μg / actuation for a 63 μl valve)1M HClFormul.Anhydrous(conc.HFAN.BDPFFGLYethanolμg / μl)134aTotal110062588563.16481073800(0.0496)210062588566.26480773800(0.0992)310062588568.76480573800(0.139)41006258856126480173800(0.188)5100625885612.56480173800(0.198)61006258856146479973800(0.222)7100625885614.56479973800(0.230)8100625885615.36479873800(0.243)9100625885616.56479773800(0.263)

Sample batches were st...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Molar densityaaaaaaaaaa
Login to view more

Abstract

Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.

Description

CROSS REFERENCES TO RELATED APPLICATIONSThis application claims priority to European Patent Application No. 09180671.1 filed on Dec. 23, 2009, which is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION1. Field of the InventionThe present invention relates to pharmaceutical aerosol solution formulations intended for use with pressurized metered dose inhalers. The present invention further relates to use of such formulations in the prevention and therapy of respiratory disorders, including chronic obstructive pulmonary disease (COPD).2. Discussion of the BackgroundGlycopyrronium bromide (also known as glycopyrrolate) is a muscarinic M3 anticholinergic agent used to reduce salivation associated with administration of certain anaesthetics, and as adjunctive therapy for peptic ulcers. It has also been reported to be effective in the treatment of asthmatic symptoms (Hansel et al., Chest, 2005; 128:1974-1979).WO 2005 / 107873 discloses the use of glycopyrrolate for...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/12A61P11/00A61P11/08B65B3/04
CPCA61K9/008A61K45/06A61K31/40A61K31/167A61K2300/00A61K31/16A61K31/573A61P11/00A61P11/06A61P11/08A61P43/00A61K9/124A61M15/009B65B3/04B65B7/285B65B31/003
Inventor BONELLI, SAUROUSBERTI, FRANCESCAZAMBELLI, ENRICO
Owner CHIESI FARM SPA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap